Low rate of sex-specific result reporting in cardiovascular trials

Mayo Clinic Proceedings

Volumn 82, Issue 2, 2007, Pages 166-170

  Blauwet, Lori A ^a   Hayes, Sharonne N ^a   Mcmanus, David ^b,d   Redberg, Rita F ^b   Walsh, Mary Norine ^c  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Care Group   (United States)

^d UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DATA ANALYSIS; FEMALE; HUMAN; MALE; MEDICAL LITERATURE; PUBLICATION; SEX DIFFERENCE;

EID: 33846677693     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.4065/82.2.166     Document Type: Article

References (38)

1. American Heart Association. Heart Disease and Stroke Statistics - 2005 Update. Available at: www.americanheart.org/downloadable/heart /1105390918119HDSStats2005Update.pdf. Accessed January 4, 2007.
2. Lansky AJ, Costa RA, Mooney M, et al, TAXUS-IV Investigators. Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol. 2005;45:1180-1185.
3. Mieres JH, Shaw LJ, Arai A, et al. Role of noninvasive testing in the clinical evaluation of women with suspected coronary artery disease: consensus statement from the Cardiac Imaging Committee, Council on Clinical Cardiology, and the Cardiovascular Imaging and Intervention Committee, Council on Cardiovascular Radiology and Intervention, American Heart Association. Circulation. 2005 Feb 8;111:682-696. Epub 2005 Feb 1.
4. Olivotto I, Maron MS, Adabag AS, et al. Gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46:480-487.
5. Johnsen SH, Joakimsen O, Fosse E, Arnesen E. Sex differences in plaque morphology may explain the higher male prevalence of myocardial infarction compared to angina pectoris: the Tromsø Study. Scand Cardiovasc J. 2005;39:3641.
6. Khor LL, Muhlestein JB, Carlquist JF, et al, Intermountain Heart Collaborative Study Group. Sex- and age-related differences in the prognostic value of C-reactive protein in patients with angiographic coronary artery disease. Am J Med. 2004;117:657-664.
7. Women's health: report of the Public Health Service Task Force on Women's Health Issues. Public Health Rep. 1985;100:73-106.
8. Inclusion of women in study populations. NIH Guide Grants Contracts. 1986 Nov 28;15(27):1.
9. US General Accounting Office. National Institutes of Health: Problems in Implementing Policy on Women in Study Populations. July 1990. GAO/T-HRD-90-50.
10. NIH/ADAMHA policy concerning inclusion of women in study populations. NIH Guide Grants Contracts. 1990 Aug 24;19(31):1.
11. NIH guidelines on the inclusion of women and minorities as subjects in clinical research. Fed Register. 1994 March 28;59:14508-14513.
12. US General Accounting Office. NIH Has Increased Its Efforts to Include Women in Research; May 2000. GAO/HEHS-00-96.
13. Department of Health and Human Services, National Institutes of Health. Monitoring Adherence to the NIH Policy on the Inclusion of Women and Minorities as Subjects in Clinical Research. Bethesda, Md: National Institutes of Health; June 2003.
14. Wizemann TM, Pardue M-L, eds. Exploring the Biological Contributions to Human Health: Does Sex Matter? Washington, DC: National Academy Press; 2001.
15. Circulation Research. Instructions to authors. Available at: http://circres .ahajournals.org/misc/ifora.shtml. Accessed January 4, 2007.
16. Journal of the American Association of Cardiology. Instructions for authors. Available at: http://content.onlinejacc.org/misc/ifora.dtl. Accessed January 4, 2007.
17. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-18477.
18. Boersma E, Harrington RA, Moliterno DJ, et al. Platelet glycoprotein IIb/ IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials [published correction appears in Lancet. 2002;359: 2120]. Lancet. 2002;359:189-198.
19. McSweeney JC, Cody M, O'Sullivan P, Elberson K, Moser DK, Garvin BJ. Women's early warning symptoms of acute myocardial infarction. Circulation. 2003 Nov 25;108:2619-2623. Epub 2003 Nov 3.
20. Kim C, Schaaf CH, Maynard C, Every NR. Unstable angina in the Myocardial Infarction Triage and Intervention Registry (MITI): short- and long-term outcomes in men and women. Am Heart J. 2001;141:73-77.
21. Jochmann N, Stangl K, Garbe E, Baumann G, Stangl V. Female-specific aspects in the pharmacotherapy of chronic cardiovascular diseases. Eur Heart J. 2005 Aug;26:1585-1595. Epub 2005 Jul 4.
22. Mackay FJ, Pearce GL, Mann RD. Cough and angiotensin II receptor antagonists: cause or confounding? Br J Clin Pharmacol. 1999;47:111-114.
23. Strocchi E, Malini PL, Valtancoli G, Ricci C, Bassein L, Ambrosioni E. Cough during treatment with angiotensin converting enzyme inhibitors: analysis of predisposing factors. Drug Invest. 1992;4:69-72.
24. Wolbrette DL. Risk of proarrhythmia with class III antiarrhythmic agents: sex-based differences and other issues. Am J Cardiol. 2003;91(6A):39D-44D.
25. Pratt CM, Camm AJ, Cooper W, et al, SWORD Investigators. Mortality in the Survival With ORal D-Sotalol (SWORD) trial: why did patients die? Am J Cardiol. 1998;81:869-876.
26. Lehmann MH, Hardy S, Archibald D, Quart B, MacNeil DJ.. Sex differences in risk of torsade de pointes with d,l-sotalol. Circulation. 1996;94:2535-2541.
27. Makker RR, Fromm BS, Steinman RT, Meissner MD, Lehmann MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA. 1993;270:2590-2597.
28. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of digoxin for the treatment of heart failure. N Engl J Med. 2002;347:1403-1411.
29. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Eng J Med. 2005 Mar 31;352:1293-1304. Epub 2005 Mar 7.
30. Grady D, Chaput L, Kristof M. Diagnosis and Treatment of Coronary Heart Disease in Women: Systemic Reviews of Evidence on Selected Topics. Evidence Report/Technology Assessment No. 81. Rockville, Md: Agency for Healthcare Research and Quality; May 2003. AHRQ publication No. 03-E037.
31. Caron J, Canadian Institutes of Health ResearchReport on governmental health research policies promoting gender or sex differences sensitivity. Available at: www.cihr-irsc.gc.ca/e/25499.html. Accessed January 4, 2007.
32. Mosca L, Appel LJ, Benjamin EJ, et al, American Heart Association. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation. 2004 Feb 10;109:672-693. Epub 2004 Feb 4.
33. Lansky AJ, Hochman JS, Ward PA, et al, American College of Cardiology Foundation, American Heart Association. Percutaneous coronary intervention and adjunctive pharmacotherapy in women: a statement for healthcare professionals from the American Heart Association. Circulation. 2005 Feb 22;111:940-953. Epub 2005 Feb 1.
34. Johnson SM, Karvonen CA, Phelps CL, Nader S, Sanborn BM. Assessment of analysis by gender in the Cochrane reviews as related to treatment of cardiovascular disease. J Womens Health (Larchmt). 2003;12:449-457.
35. Meinert CL, Gilpin AK. Estimation of gender bias in clinical trials. Stat Med. 2001;20:1153-1164.
36. Meinert CL, Gilpin AK, Unalp A, Dawson C. Gender representation in trials. Control Clin Trials. 2000;21:462-475.
37. Vidaver RM, Lafleur B, Tong C, Bradshaw R, Marts SA. Women subjects in NIH-funded clinical research literature: lack of progress in both representation and analysis by sex. J Womens Health Gend Based Med. 2000;9:495-504.
38. Harris DJ, Douglas PS. Enrollment of women in cardiovascular clinical trials funded by the National Heart, Lung, and Blood Institute. N Engl J Med. 2000;343:475-480.